Kyowa Hakko Kirin Co., Ltd.
1-6-1, Ohtemachi
Chiyoda-ku
Tokyo, 100-8185
Japan
Phone: 81 3 3282 0007
Fax: 81 3 3284 1968
Website:
http://www.kyowa-kirin.co.jp
Kyowa Hakko Kirin Co., Ltd. manufactures and markets pharmaceuticals and bio-chemicals primarily in Asia, Europe, and the United States. The company’s Pharmaceuticals segment researches, develops, produces, and sells ethical drugs for the treatment of various diseases, including renal anemia, oncology, allergies, and hypertension. Its principal ethical drugs include NESP/ESPO, an ESA formulation; REGPARA, a secondary hyperparathyroidism; CONIEL, a hypertension and angina pectoris; ONGLYZA, a treatment for type 2 diabetes; GRAN, a G-CSF agent; Fentos, a transdermal product; POTELIGEO, an adult T-cell leukemia-lymphoma; Romiplate, a chronic idiopathic thrombocytopenic purpur; ALLELOCK, an antiallergic agent; Patanol antiallergic eye drops; ASACOL, an ulcerative colitis treatment; NOURIAST, an antiparkinsonian agent; and DEPAKENE, an antiepileptic agent. This segment also offers in vitro diagnostic reagents, such as POTELIGEO tests and Determiner clinical chemistry diagnostic reagents. The company’s Bio-chemicals segment produces and sells amino acids, nucleotides, and related compounds for use in pharmaceuticals and their intermediates, health foods, dietary supplements, and cosmetics. This segment also produces plant growth regulators; designs and installs plant facilities and equipment; manufactures active pharmaceutical ingredients, pharmaceutical intermediates, industrial raw materials, and health care products; sale of fine chemicals; and is involved in mail-order sale of healthcare products in Japan. In addition, the company is engaged in pharmaceuticals licensing, as well as insurance, wholesale, and retail activities. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.